Abstracts tagged "Patient reported outcomes"

Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0158 • ACR Convergence 2020
Relationships Between Disease Patterns in RA and Rheumatology Treatment
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: We previously showed rheumatoid arthritis (RA) patients report diversity in disease activity (DA) patterns that may be associated with treatment response. Patients who describe…
Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Courtney Stull¹, Soumya Reddy², M. Elaine Husni³, Jose Scher⁴, Ethan Craig¹, Jessica Walsh⁵ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Cleveland Clinic, Cleveland, OH, ⁴NYU School of Medicine, New York City, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…
Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Kevin Kennedy¹, Emily Sirotich², Salman Surangiwala³, Maggie Larche², Mitchell Levine¹ and Jonathan Hausmann⁴, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…
Abstract Number: 1126 • ACR Convergence 2020
A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study
Dana DiRenzo¹, Carly Hunt², Erica Sibinga², Neda Gould², Ami Shah³, Susan Bartlett⁴ and Clifton Bingham III¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴McGill University, Montreal, Canada
Background/Purpose: Mindfulness Based Interventions (MBIs) are well-established self-management programs shown to be beneficial for pain, depression, and anxiety that focus on learning how to respond…
Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Gerd Burmester¹, Laure Gossec², Hubert van Hoogstraten³, Amy Praestgaard⁴, Gregory St John⁵, Thomas Huizinga⁶, Daniel Aletaha⁷ and Roy Fleischmann⁸, ¹Charité University Hospital Berlin, Berlin, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…
Abstract Number: 1469 • ACR Convergence 2020
Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
Jonathan Hausmann¹, Kevin Kennedy², Salman Surangiwala³, Maggie Larche⁴, Mitchell Levine², Jean Liew⁵, Zachary Wallace⁶ and Emily Sirotich⁴, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Washington, Seattle, WA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with rheumatic diseases are at increased risk of infection due to immune dysregulation and the use of immunosuppression. It is unknown whether they…
Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³, Minako Sato⁴, Masaru Tanaka⁴, Katsunori Ikari¹, Atsuo Taniguchi¹, Hisashi Yamanaka⁵ and Masayoshi Harigai⁶, ¹Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…
Abstract Number: PP08 • ACR Convergence 2020
Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up
Carly Harrison¹, Rashmi Sinha², Emily Sirotich³, Naira Ikram⁴, Kristen Young⁵, Christele Felix¹, Karen Durrant⁶, Richard Beesley⁷, Serena Mingolla⁸, Ana Isabel Martín Mancheño⁹, Dawn Richards¹⁰, Evelyn Olmedo¹¹, Wendy Costello¹², Monique Gore-Massy¹³, Laurie Proulx¹⁴, Maria Marino¹⁵ and Richard Howard¹⁶, ¹LupusChat, New York, NY, ²Systemic JIA Foundation, Cincinnati, OH, ³LA Lupus Lady, Hamilton, ON, Canada, ⁴Duke University, Austin, TX, ⁵Phoenix, AR, ⁶Autoinflammatory Alliance, San Francisco, CA, ⁷Juvenile Arthritis Research, United Kingdom, ⁸Associazione Nazionale Persone con Malattie Reumatolgiche e Rare APMARR APS, Brindisi, Italy, ⁹CEADE, Madrid, Spain, ¹⁰Canadian Arthritis Patient Alliance, Toronto, ON, Canada, ¹¹Buenos Aires, El Salvador, ¹²iCAN, Bansha, Tipperary, Ireland, ¹³Lupus Foundation of America, Brooklyn, NY, ¹⁴Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ¹⁵Arthritis Foundation; Vectra, Athens, GA, ¹⁶Spondylitis Association of America, Van Nuys, CA
Background/Purpose: The COVID-19 Global Rheumatology Alliance (GRA) is a volunteer-driven organization that originated in response to the global pandemic. It was created to improve patient…
Abstract Number: 2692 • 2015 ACR/ARHP Annual Meeting
The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound
Hilde Berner Hammer¹ and Jon Lampa², ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Patient reported outcomes (PROs) are important for evaluation of treatment response in patients with rheumatoid arthritis (RA). Ultrasound (US) is a sensitive method for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].